https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39611 Thu 16 Jun 2022 10:15:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30828 50% or PPV >65% for either cancer type and no combination of indicators increased both the sensitivity and PPV above that achieved using the hospital cancer diagnosis data. All specificities were close to 100%; 95% confidence intervals for sensitivity and PPV were generally +/−2%. Conclusions: In NSW, identifying new cases of colorectal and lung cancer from administrative health datasets, such as hospital records, is a feasible alternative when cancer registry data are not available. However, the strengths and limitations of the different data sources should be borne in mind.]]> Thu 13 Jan 2022 10:30:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18868 3 and 101–200 cells/mm3 were statistically significantly less likely to have virological failure, compared to those with a baseline CD4 count lower than 50 cells/mm ³ (OR=0.61, 95% CI 0.23–0.89; and OR=0.43, 0.18–0.78, respectively). In contrast, patients with a history of injecting drug use were statistically significantly more likely to have viraemia than otherwise (OR=1.32, 1.16–1.67). The PPV of the WHO immunological criteria was 60.1% (57.1–69.3%). Conclusions: Routine viral load tests should be conducted early to detect virological failure and prevent unnecessary changes to second-line treatments. To improve treatment outcomes, timely ART initiation and adherence to treatment among those with history of injecting drug use should be promoted.]]> Sat 24 Mar 2018 08:03:14 AEDT ]]>